Melanoma News and Research

Latest Melanoma News and Research

Antioxidants can increase rate of melanoma metastasis in mice

Fresh research at Sahlgrenska Academy has found that antioxidants can double the rate of melanoma metastasis in mice. The results reinforce previous findings that antioxidants hasten the progression of lung cancer. According to Professor Martin Bergö, people with cancer or an elevated risk of developing the disease should avoid nutritional supplements that contain antioxidants.

9 Oct 2015

Skin cancer rates higher among gay and bisexual men, UCSF-led study finds

Gay and bisexual men were up to six times more likely than heterosexual men to take part in indoor tanning, and twice as likely to report a history of skin cancer, including nonmelanoma and melanoma, according to a study led by UC San Francisco researchers.

8 Oct 2015

2-year advanced melanoma survival benefit with dabrafenib, trametinib combination

Updated results from the COMBI-v trial show significantly improved overall and progression-free survival with first-line dabrafenib plus trametinib compared with vemurafenib in patients with advanced melanoma.

7 Oct 2015

Nivolumab, ipilimumab duo effective in poor prognosis advanced melanoma patients

Subgroups of advanced melanoma patients with a poor prognosis derive a progression-free survival benefit from the combination of nivolumab and ipilimumab, according to research presented at the European Cancer Congress in Vienna, Austria.

5 Oct 2015

Height may be linked to cancer risk

Taller individuals are more likely to develop cancer than shorter people, according to the results of a study presented at the 54th Annual European Society for Pediatric Endocrinology Meeting in Barcelona.

2 Oct 2015

Cornell University, MSKCC jointly open new $10 million Center of Cancer Nanotechnology Excellence

Cornell University, in partnership with Memorial Sloan Kettering Cancer Center, is opening a new $10 million Center of Cancer Nanotechnology Excellence that brings together scientists, engineers, biologists and physicians to develop and translate new cancer care applications based on nanotechnology.

30 Sep 2015

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.

29 Sep 2015

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.

28 Sep 2015

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Kolltan Pharmaceuticals, Inc. today announced the presentation of data from a preclinical study evaluating KTN0158 in dogs with spontaneous mast cell tumors. KTN0158 is a proprietary, humanized anti-KIT IgG1 monoclonal antibody drug candidate being developed as a potential therapy for cancer and mast cell-related diseases.

28 Sep 2015

Two-drug combination improves progression-free survival in patients with advanced melanoma

Patients with advanced melanoma skin cancer survive for longer without their disease progressing if they have been treated with a combination of two drugs, nivolumab and ipilimumab, than with either of these drugs alone. New results show that these patients also do better regardless of their age, stage of disease and whether or not they have a cancer-driving mutation in the BRAF gene.

28 Sep 2015

Combination of two targeted therapies increases survival in advanced melanoma

Latest results from a trial of a combination of two targeted therapies (dabrafenib and trametinib) to treat advanced melanoma have shown that patients are living significantly longer on the combined therapy than patients treated with another drug, vemurafenib, when used alone.

28 Sep 2015

Researchers find mutated gene responsible for cardiac angiosarcoma in two brothers

A few years ago, Javier Benítez, director of the Human Genetics Group at the CNIO, received a call from Pablo García Pavía, from the Cardiology Unit of the Puerta de Hierro University Hospital. This cardiologist was treating two brothers with a rare form of cancer, cardiac angiosarcoma (CAS).

26 Sep 2015

Arteries may be best source for detecting circulating tumor cells

As the field of liquid biopsies for tracking disease progression and therapeutic response heats up, many doctors are looking for ways to apply this approach to their patients.

26 Sep 2015

EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

Comparisons of cancer patients' survival and care in Europe up to 2007 show that although more patients are surviving for at least five years after diagnosis, there are large variations between countries, which are particularly significant in cancers of the blood.

26 Sep 2015

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited.

26 Sep 2015

JRC, CERN to explore potential of accelerator-driven method for producing targeted alpha therapy for cancer

A novel, accelerator-driven method could produce nuclides for targeted alpha therapy of cancer in practically unlimited amounts, overcoming current obstacles for its wider use due to a limited production of alpha-emitters. The JRC and the Conseil Européen pour la Recherche Nucléaire have embarked to explore the potential of the jointly proposed method.

24 Sep 2015

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun Phase II of another arm of its multi-arm clinical trial that combines immunotherapy with chemotherapy.

21 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

EORTC trial evaluates effectiveness of pembrolizumab in patients with high-risk stage III melanoma

A recently opened double- blind phase III EORTC trial 1325 will prospectively assess whether post-operative adjuvant therapy with pembrolizumab, an anti-PD-1 monoclonal antibody, improves recurrence-free survival as compared to placebo in patients with high-risk stage III melanoma.

15 Sep 2015

Researchers show how a cell surface protein can mobilize immune cells to attack malignant tumors

Revealing a biological combat strategy worthy of a five-star general, researchers from Houston Methodist Hospital, University of Chicago and Cornell University have shown how a cell surface receptor--a specialized protein which communicates signals between a cell and the outside world--can mobilize immune cells to attack, rather than protect, malignant tumors.

15 Sep 2015

Melanoma News and Research

Latest Melanoma News and Research

Antioxidants can increase rate of melanoma metastasis in mice

Skin cancer rates higher among gay and bisexual men, UCSF-led study finds

2-year advanced melanoma survival benefit with dabrafenib, trametinib combination

Nivolumab, ipilimumab duo effective in poor prognosis advanced melanoma patients

Height may be linked to cancer risk

Cornell University, MSKCC jointly open new $10 million Center of Cancer Nanotechnology Excellence

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Two-drug combination improves progression-free survival in patients with advanced melanoma

Combination of two targeted therapies increases survival in advanced melanoma

Researchers find mutated gene responsible for cardiac angiosarcoma in two brothers

Arteries may be best source for detecting circulating tumor cells

EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

JRC, CERN to explore potential of accelerator-driven method for producing targeted alpha therapy for cancer

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

EORTC trial evaluates effectiveness of pembrolizumab in patients with high-risk stage III melanoma

Researchers show how a cell surface protein can mobilize immune cells to attack malignant tumors

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Melanoma News and Research

Latest Melanoma News and Research

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in